

Bozlu Holding, Turkey's Integrated Healthcare Services Provider initiates New Partnership

Bozlu Holding of Turkey has recently invested in 50% ownership in DDD Diagnostic of Denmark. This is the latest investment of Bozlu; which grows with new investments in high entry threshold sectors which require expertise and advanced technology in Turkey and abroad. Active in nuclear medicine field for more than 23 years, Bozlu has now stepped into the production of gamma camera systems with this investment.

Touching upon Bozlu's strategic development plan, Chairman of Bozlu Holding, Mr. Şükrü Bozluoçay notes the following with regards to the new partnership, "In the framework of our 10 year strategy, similar partnerships and acquisitions where we will be active in management and day-to-day operations will follow which will augment our vertically integrated structure. We shall continue to pursue different opportunities which will carry us further on our sustainable growth path."

DDD Diagnostic has been in the nuclear medicine market as developer and manufacturer of molecular imaging systems since 1987. DDD Diagnostic is located in Hørsholm, just north of Copenhagen, Denmark. The company holds leadership position especially in nuclear cardiology. With an emphasis on design and quality, DDD manufactures diagnostic imaging devices for world's leading companies.

In 2013, DDD has also released products to the market under its own brand. The product line consists of the Solo, a single-detector system for small organ planar imaging, also in a mobile version with integrated battery and the NephroCam for Radioisotope Renography. A Variable Angle SPECT camera, the QuantumCam, for General Purpose Nuclear Medicine was released early 2013. The most recent system released is the CorCam for nuclear cardiology procedures. DDD-Diagnostic is represented with own branded products in more than 60 countries.

Mr. Lars Trolle, CEO of DDD Diagnostic, adds to the Bozlu partnership agreement, "The journey of DDD enters into a new and exciting phase, with the Bozlu Group of companies. I am sure that Bozlu's innovation and nuclear medicine track record will be to the benefit of DDD".

This new partnership will facilitate DDD and Bozlu Holding to draw upon each other's strengths to create innovative products and a stronger structure. Combining Bozlu Holding's nuclear medicine vision and market knowledge with DDD's emphasis on quality, design and solid engineering, the newly developed DDD products will be marketed globally to a broader and deeper base.

For further information, please contact:

Bozlu Holding
Ms. Asli Bozluoçay
asli.bozluoçay@bozlu.com

DDD-Diagnostic A/S
Mr. Lars Trolle
lars.trolle@ddd-diagnostic.dk